Edwards Lifesciences Presents New Data on Heart Disease Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: Newsfilter
Edwards Lifesciences Corp's stock rose by 3.01% as it reached a 52-week high amid a challenging market environment where the Nasdaq-100 is down 0.70% and the S&P 500 is down 0.07%.
The company unveiled significant findings at the New York Valves 2026 conference, showcasing data from the PROGRESS trial that indicates over 95% of moderate aortic stenosis patients are symptomatic. This trial aims to assess the benefits of transcatheter aortic valve replacement (TAVR) for these patients earlier than current guidelines suggest, which could revolutionize treatment strategies. Additionally, long-term durability data from the PARTNER 3 trial reinforces the efficacy of the SAPIEN 3 platform, further establishing Edwards' leadership in heart disease treatment.
These developments not only highlight Edwards Lifesciences' commitment to innovation in heart disease therapies but also position the company favorably in a competitive market, potentially leading to increased adoption of its technologies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EW?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EW
Wall Street analysts forecast EW stock price to rise
24 Analyst Rating
16 Buy
8 Hold
0 Sell
Moderate Buy
Current: 89.720
Low
84.00
Averages
96.52
High
105.00
Current: 89.720
Low
84.00
Averages
96.52
High
105.00
About EW
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Edwards Lifesciences Unveils New Data Reinforcing Leadership in Heart Disease Treatment
- Clinical Trial Progress: At the New York Valves 2026 conference, Edwards Lifesciences presented baseline characteristics from the PROGRESS trial, revealing that over 95% of moderate aortic stenosis patients were symptomatic, with more than 70% exhibiting two or more risk features, highlighting the company's innovative potential in heart disease treatment.
- Treatment Optimization: The PROGRESS trial aims to evaluate whether moderate aortic stenosis patients can benefit from transcatheter aortic valve replacement (TAVR) earlier than current guidelines suggest, potentially altering existing clinical monitoring strategies and improving patient treatment timing.
- Long-term Durability Data: Seven-year benchmark durability data from the PARTNER 3 trial were simultaneously published, further solidifying the therapeutic efficacy of the SAPIEN 3 platform, indicating the long-term application value of this technology in heart disease patients.
- Technology and Evidence Integration: By analyzing data from over 4,500 patients treated with the PASCAL system, Edwards emphasizes the safety and effectiveness of its technology in mitral regurgitation treatment, further enhancing the company's leadership position in the structural heart disease sector.
See More
U.S. Stocks Close Mixed: Dow Hits All-Time High
- Dow Hits All-Time High: The Dow Jones Industrial Average rose by 0.64%, reaching a new all-time high, reflecting investor confidence in economic recovery, despite mixed overall market performance indicating divergent views among investors on various sectors.
- Chip Stocks Decline: With Marvell Technology and Intel falling over 9% and 8% respectively, the weakness in chipmakers weighed on the broader market, suggesting that the pressure on tech stocks may impact future investment sentiment.
- Weak Housing Data: U.S. May housing starts fell 15.4% month-over-month to a six-year low of 1.177 million, below expectations of 1.430 million, indicating that the weakness in the housing market could pose challenges to economic growth.
- Oil Prices Plummet: WTI crude oil prices dropped more than 5% to a 3.5-month low due to the U.S.-Iran agreement to reopen the Strait of Hormuz, enhancing expectations for a revival in oil supplies, which may affect the performance of energy stocks.
See More
Edwards Lifesciences Shares Hit New 52-Week High
- Medicare Coverage Expansion: The U.S. Centers for Medicare & Medicaid Services proposed expanding coverage for transcatheter aortic valve replacement (TAVR) to include asymptomatic severe aortic stenosis, significantly enhancing Edwards Lifesciences' market potential.
- Positive Competitor Response: Rivals Medtronic and Abbott Laboratories also saw their shares rise in response to the proposal, indicating a broader market optimism in the TAVR space that could further drive industry growth.
- Enhanced Procedural Efficiency: Analysts noted that the proposal could eliminate dual-operator intraoperative requirements and multiple hospital-level volume requirements, thereby improving procedural efficiency at established TAVR centers and lowering barriers for new program adoption, enhancing competitive positioning.
- Increased Investor Confidence: Evercore ISI analysts argue that the proposal is extremely bullish for Edwards Lifesciences, with expectations of a low-to-mid single-digit percentage increase in stock price, reflecting market optimism regarding the company's future growth prospects.
See More
Mixed US Stock Market with Energy Stocks Under Pressure
- Market Divergence: The S&P 500 Index fell by 0.18% and the Nasdaq 100 Index dropped by 0.83%, while the Dow Jones Industrial Average rose by 0.69% to a new all-time high, indicating a divergence in market performance, particularly as energy stocks are pressured by plunging crude oil prices.
- Weak Housing Data: US May housing starts fell by 15.4% month-over-month to a six-year low of 1.177 million, significantly below the expected 1.430 million, while building permits also declined slightly, reflecting weakness in the real estate market that could negatively impact overall economic growth.
- Oil Price Impact on Sentiment: WTI crude oil prices dropped over 3% to a 3.25-month low due to the US-Iran agreement to reopen the Strait of Hormuz, which has eased inflation expectations; while this provides short-term support for stocks, the long-term effects remain to be seen.
- Fed Meeting Focus: The market is turning its attention to the two-day FOMC meeting, where rates are expected to remain unchanged, but the press conference led by new Chair Kevin Warsh will be crucial, as investors will look for insights on future inflation outlook and policy direction.
See More
Mixed Performance in US Stock Indices Amid Energy Sector Pressure
- Mixed Market Performance: The S&P 500 Index rose by 0.11%, the Dow Jones Industrial Average increased by 0.57%, while the Nasdaq 100 Index fell by 0.18%, indicating a complex market sentiment particularly influenced by the pressure on energy stocks due to declining oil prices.
- Oil Price Impact: WTI crude oil prices dropped over 3% to a 3.25-month low, easing inflation expectations and providing support for stocks and bonds, reflecting a cautious market outlook on future economic growth.
- Weak Housing Data: US May housing starts fell by 15.4% month-over-month to a six-year low of 1.177 million, below the expected 1.430 million, indicating potential challenges for economic recovery stemming from a sluggish real estate market.
- FOMC Meeting Focus: Market attention shifts to the two-day FOMC meeting, where rates are expected to remain unchanged, but the press conference led by new Chair Kevin Warsh will be pivotal in shaping future monetary policy directions.
See More
Edwards Lifesciences Corp. Latest Developments
- Company History and Achievements: Founded in 1960, Edwards Lifesciences made history with the first commercially available artificial heart valve, helping over two million cardiac patients worldwide and achieving a market capitalization of $46 billion, underscoring its significance in the medical device industry.
- Strong Growth Momentum: In Q1 2026, the company's heart-related therapies business posted approximately 42% year-over-year growth, prompting an upward revision of full-year sales growth guidance to 9%-11%, with projected revenues between $6.5 billion and $6.9 billion, reflecting robust market demand.
- Improved Profitability: The adjusted EPS guidance was raised to $2.95-$3.05, with operating margins expected at the high end of the 28%-29% range, indicating ongoing enhancements in profitability that bolster investor confidence.
- Technical and Market Strategy: Edwards' stock consolidated between $75 and $87 over the past six months, and after breaking out, it retraced to the $81 area and rebounded, signaling strong buying interest; the healthy RSI indicates sustained bullish sentiment, making it suitable for momentum investment strategies.
See More
Edwards Lifesciences Unveils New Data Reinforcing Leadership in Heart Disease Treatment
- Clinical Trial Progress: At the New York Valves 2026 conference, Edwards Lifesciences presented baseline characteristics from the PROGRESS trial, revealing that over 95% of moderate aortic stenosis patients were symptomatic, with more than 70% exhibiting two or more risk features, highlighting the company's innovative potential in heart disease treatment.
- Treatment Optimization: The PROGRESS trial aims to evaluate whether moderate aortic stenosis patients can benefit from transcatheter aortic valve replacement (TAVR) earlier than current guidelines suggest, potentially altering existing clinical monitoring strategies and improving patient treatment timing.
- Long-term Durability Data: Seven-year benchmark durability data from the PARTNER 3 trial were simultaneously published, further solidifying the therapeutic efficacy of the SAPIEN 3 platform, indicating the long-term application value of this technology in heart disease patients.
- Technology and Evidence Integration: By analyzing data from over 4,500 patients treated with the PASCAL system, Edwards emphasizes the safety and effectiveness of its technology in mitral regurgitation treatment, further enhancing the company's leadership position in the structural heart disease sector.
See More
U.S. Stocks Close Mixed: Dow Hits All-Time High
- Dow Hits All-Time High: The Dow Jones Industrial Average rose by 0.64%, reaching a new all-time high, reflecting investor confidence in economic recovery, despite mixed overall market performance indicating divergent views among investors on various sectors.
- Chip Stocks Decline: With Marvell Technology and Intel falling over 9% and 8% respectively, the weakness in chipmakers weighed on the broader market, suggesting that the pressure on tech stocks may impact future investment sentiment.
- Weak Housing Data: U.S. May housing starts fell 15.4% month-over-month to a six-year low of 1.177 million, below expectations of 1.430 million, indicating that the weakness in the housing market could pose challenges to economic growth.
- Oil Prices Plummet: WTI crude oil prices dropped more than 5% to a 3.5-month low due to the U.S.-Iran agreement to reopen the Strait of Hormuz, enhancing expectations for a revival in oil supplies, which may affect the performance of energy stocks.
See More
Edwards Lifesciences Shares Hit New 52-Week High
- Medicare Coverage Expansion: The U.S. Centers for Medicare & Medicaid Services proposed expanding coverage for transcatheter aortic valve replacement (TAVR) to include asymptomatic severe aortic stenosis, significantly enhancing Edwards Lifesciences' market potential.
- Positive Competitor Response: Rivals Medtronic and Abbott Laboratories also saw their shares rise in response to the proposal, indicating a broader market optimism in the TAVR space that could further drive industry growth.
- Enhanced Procedural Efficiency: Analysts noted that the proposal could eliminate dual-operator intraoperative requirements and multiple hospital-level volume requirements, thereby improving procedural efficiency at established TAVR centers and lowering barriers for new program adoption, enhancing competitive positioning.
- Increased Investor Confidence: Evercore ISI analysts argue that the proposal is extremely bullish for Edwards Lifesciences, with expectations of a low-to-mid single-digit percentage increase in stock price, reflecting market optimism regarding the company's future growth prospects.
See More
Mixed US Stock Market with Energy Stocks Under Pressure
- Market Divergence: The S&P 500 Index fell by 0.18% and the Nasdaq 100 Index dropped by 0.83%, while the Dow Jones Industrial Average rose by 0.69% to a new all-time high, indicating a divergence in market performance, particularly as energy stocks are pressured by plunging crude oil prices.
- Weak Housing Data: US May housing starts fell by 15.4% month-over-month to a six-year low of 1.177 million, significantly below the expected 1.430 million, while building permits also declined slightly, reflecting weakness in the real estate market that could negatively impact overall economic growth.
- Oil Price Impact on Sentiment: WTI crude oil prices dropped over 3% to a 3.25-month low due to the US-Iran agreement to reopen the Strait of Hormuz, which has eased inflation expectations; while this provides short-term support for stocks, the long-term effects remain to be seen.
- Fed Meeting Focus: The market is turning its attention to the two-day FOMC meeting, where rates are expected to remain unchanged, but the press conference led by new Chair Kevin Warsh will be crucial, as investors will look for insights on future inflation outlook and policy direction.
See More
Mixed Performance in US Stock Indices Amid Energy Sector Pressure
- Mixed Market Performance: The S&P 500 Index rose by 0.11%, the Dow Jones Industrial Average increased by 0.57%, while the Nasdaq 100 Index fell by 0.18%, indicating a complex market sentiment particularly influenced by the pressure on energy stocks due to declining oil prices.
- Oil Price Impact: WTI crude oil prices dropped over 3% to a 3.25-month low, easing inflation expectations and providing support for stocks and bonds, reflecting a cautious market outlook on future economic growth.
- Weak Housing Data: US May housing starts fell by 15.4% month-over-month to a six-year low of 1.177 million, below the expected 1.430 million, indicating potential challenges for economic recovery stemming from a sluggish real estate market.
- FOMC Meeting Focus: Market attention shifts to the two-day FOMC meeting, where rates are expected to remain unchanged, but the press conference led by new Chair Kevin Warsh will be pivotal in shaping future monetary policy directions.
See More
Edwards Lifesciences Corp. Latest Developments
- Company History and Achievements: Founded in 1960, Edwards Lifesciences made history with the first commercially available artificial heart valve, helping over two million cardiac patients worldwide and achieving a market capitalization of $46 billion, underscoring its significance in the medical device industry.
- Strong Growth Momentum: In Q1 2026, the company's heart-related therapies business posted approximately 42% year-over-year growth, prompting an upward revision of full-year sales growth guidance to 9%-11%, with projected revenues between $6.5 billion and $6.9 billion, reflecting robust market demand.
- Improved Profitability: The adjusted EPS guidance was raised to $2.95-$3.05, with operating margins expected at the high end of the 28%-29% range, indicating ongoing enhancements in profitability that bolster investor confidence.
- Technical and Market Strategy: Edwards' stock consolidated between $75 and $87 over the past six months, and after breaking out, it retraced to the $81 area and rebounded, signaling strong buying interest; the healthy RSI indicates sustained bullish sentiment, making it suitable for momentum investment strategies.
See More
